NEW YORK, March 07, 2016 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of PTC Therapeutics, Inc. (“PTC” or the “Company”) (Nasdaq:PTCT) between May 6, 2014 and February 23, 2016.
You are hereby notified that a securities class action has been commenced in the USDC for the District of New Jersey. If you purchased or otherwise acquired PTC securities between May 6, 2014 and February 23, 2016, your rights may be affected by this action. To get more information go to: http://www.zlk.com/pslra/ptc-therapeutics.
The Complaint alleges that throughout the Class Period, defendants made materially false and misleading statements, and omitted materially adverse facts, about the Company’s business, operations and prospects. As a result of defendants’ alleged false and misleading statements, the Company’s stock traded at artificially inflated prices during the Class Period.
According to the Complaint, on February 23, 2016, PTC announced that it received a Refuse to File letter from the United States Food and Drug Administration (“FDA”) regarding the New Drug Application for Translarna. The FDA stated in the Refuse to File letter that the application was not sufficiently complete to permit a substantive review. On this news, shares of PTC fell over 61%, closing at $10.84 per share on February 23, 2016, on heavy trading volume.
If you suffered a loss in PTC you have until May 2, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://www.zlk.com/pslra/ptc-therapeutics.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Eduard Korsinsky, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com


SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes
Meta Expands AI Training With Employee Activity Tracking Tools
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions
John Ternus Signals Apple’s Future with Product-First AI Strategy 



